Skip to main content

Table 4 Impact of (D8-D1) variations on PFS in univariate and multivariate analysesa

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Parameters Univariate analysis Multivariate analysisc
HRb (95% CI) p HRb (95% CI) p
Variation (D8-D1)
 Human FGF (pg/mL) 1.24 (1.10–1.39) < 0.001 1.16 (1.03–1.31) 0.016
 PlGF (pg/mL) 1.01 (0.98–1.04) 0.51   
 SCF sR/c-kit (ng/mL) 1.04 (0.74–1.45) 0.83   
 sE-Selectin (ng/mL) 0.99 (0.96–1.01) 0.46   
 TSP-1 (μg/mL) 1.00 (0.99–1.01) 0.98   
 VEGF (ng/mL) 1.30 (0.30–5.65) 0.73   
 VEGF-C (ng/mL) 1.08 (0.83–1.42) 0.57   
  1. aConsidering the absence of difference statistically significant, the data from the two arms were pooled
  2. bFor each biomarker, HR represents the hazard ratio for an increase of one unit, as estimated including the baseline value
  3. cFactors associated with PFS with p < 0.20 in univariate analysis were included in a stepwise multivariate model: tumor location, medical history, PIGF on D1, VEGF-C on D1 and variation (D8-D1) of human FGF. Only medical history, VEGF-C on D1 and human FGF variation (D8-D1) were significantly associated with PFS in multivariate analysis. The HR for variation (D8-D1) of human FGF adjusted by medical history and VEGF-C by D1 is presented in the table. The adjusted HRs for medical history and biomarker on D1 were de novo = 2.39 (95% CI: 1.09–5.26), p = 0.030, and VEGF-C = 0.73 (0.57–0.94), p = 0.015, respectively. Other parameters were associated with PFS with a p-value > 0.05 and were removed from the model: tumor location (HR = 1.33 (95% CI: 0.61–2.90), p = 0.47) and PIGF pg/mL on D1 (HR = 1.00 (95%CI: 0.98–1.03), p = 0.70)